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Abstract
Objectives:To determine whether prolonged intensive disease-modifying antirheumatic drug (DMARD) treatment (PRINT) leads to
high remission and low relapse rates in patients with severe rheumatoid arthritis (RA).
Methods: In this multicenter, randomized and parallel treatment trial, 346 patients with active RA (disease activity score (28 joints)
[DAS28] (erythrocyte sedimentation rate [ESR])> 5.1) were enrolled from 9 centers. In phase 1, patients received intensive treatment
with methotrexate, leflunomide, and hydroxychloroquine, up to 36 weeks, until remission (DAS28 2.6) or a low disease activity (2.6
< DAS28 3.2) was achieved. In phase 2, patients achieving remission or low disease activity were followed up with randomization
to 1 of 2 step-down protocols: leflunomide plus hydroxychloroquine combination or leflunomide monotherapy. The primary
endpoints were good European League Against Rheumatism (EULAR) response (DAS28 (ESR)< 3.2 and a decrease of DAS28 by at
least 1.2) during the intensive treatment and the disease state retention rate during step-down maintenance treatment. Predictors of
a good EULAR response in the intensive treatment period and disease flare in the maintenance period were sought.
Results:A good EULAR response was achieved in 18.7%, 36.9%, and 54.1% of patients at 12, 24, and 36 weeks, respectively. By
36 weeks, 75.4% of patients achieved good and moderate EULAR responses. Compared with those achieving low disease activity
and a high health assessment questionnaire (HAQ > 0.5), patients achieving remission (DAS28  2.6) and low HAQ ( 0.5) had a
significantly higher retention rate when tapering the DMARDs treatment (P=0.046 and P=0.01, respectively). There was no
advantage on tapering to combination rather than monotherapy.
Conclusions: Remission was achieved in a proportion of patients with RA receiving prolonged intensive DMARD therapy. Low
disease activity at the start of disease taper leads to less subsequent flares. Leflunomide is a good maintenance treatment as single
treatment.
Abbreviations: AE = adverse events, anti-CCP = anticyclic citrullinated peptide, CRP = C-reactive protein, DAS28 = disease
activity score (28 joints), DMARD = disease-modifying antirheumatic drug, ESR = erythrocyte sedimentation rate, EULAR =
European League Against Rheumatism, HCQ = hydroxychloroquine, LDA = low disease activity, LEF = leflunomide, MGA =medicalEditor: Carlos Guillen Astete.
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global assessment, MTX = methotrexate, PGA = patient global assessment, RA = rheumatoid arthritis, RF = rheumatoid factor,
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Rheumatoid arthritis (RA) is a chronic autoimmune disease
characterized by synovitis, cartilage damage, and bone erosion,
leading to deformity and disability. Clinical remission or low
disease activity (LDA) is the recommended treatment target in
patients with RA.[1] Conventional disease-modifying antirheu-
matic drugs (DMARDs) remain the core medications employed
in daily practice in many parts of the world.[2] Intensive treatment
using combinations of DMARDs is proposed to be superior to
routine step-up DMARD treatment.[3–6] However, in clinical
practice, after patients achieve the treatment target, DMARDs
are often tapered.[1,7] It has been reported that the risk of flare is
higher in patients tapering DMARDs early than those continuing
therapy.[8,9] Few studies have directly addressed the optimal
approach to tapering. We hypothesized that prolonged intensive
DMARD therapy will result in a high proportion of patients
achieving remission and subsequently few patients relapsing
upon DMARD tapering.2. Methods
2.1. Trial design and participants
We performed a controlled randomized, single-blinded, parallel
treatment trial of tapering protocols after initial intensive
DMARD therapy. Nine hospitals in China collaborated and
enrolled patients from July 2009 to June 2010. Follow-up was
ended in March 2012. Key inclusion criteria were as follows: RA
according to the 1987 revised American College of Rheumatolo-
gy criteria[10]; disease activity score (28 joints) (DAS28)> 5.1 and
age >18 years. Key exclusion criteria were previous use of
prednisone>10mg orally, chronic liver disease, cancer, excessive
alcohol use, pregnancy (intended), or laboratory abnormalities:
leucopenia (<4.0109/L), thrombocytopenia (<100109/L),
elevated aspartate aminotransferase, alanine aminotransferase,
and creatinine level.
The study was approved by Peking University People’s
Hospital’s ethics committee. All patients gave written informed
consent. This trial was registered inWorld Health Organization’s
International Clinical Trial Registry Platform with www.chictr.
org (No. ChiCTR-TRC-09000469).2.2. Randomization
Patients who achieved LDA during an open-label induction
period were eligible for the step-down maintenance stage, and
were randomly assigned by sealed opaque envelope containing
computer-generated random allocations in a 1:1 ratio to 1 of 2
treatment groups. The statistician who generated the randomi-
zation sequence was not otherwise involved in the trial.2.3. Interventions
There were 2 phases in the study. In phase 1, enrolled patients
received DMARDs treatment comprising a combination of
methotrexate (MTX), leflunomide (LEF), and hydroxychloroquine2(HCQ). The starting dose of oral MTX was 7.5mg/wk that could
be increased to a maximum of 20mg/wk. LEF (10–20mg/d per
rheumatologists’ discretion) and HCQ (400mg/d) were adminis-
trated in combinationwithMTX.Adverse events (AEs) and serious
AEs were recorded throughout the study. Folic acid was
administered to every patient (5mg/wk, 1 single dose). Use of
nonsteroidal anti-inflammatory drugs was allowed and the dose
could be changed in the study. Intra-articular or intramuscular
injection of glucocorticoids was allowed only once (no more than
40mg Triamcinolone Acetonide or its equivalent) at the beginning
of the study. Oral glucocorticoids (prednisone  10mg/d) were
allowed but were tapered to discontinuation before entering the
step-downmaintenance period. Disease activity was assessed every
12 weeks. Patients who achieved a DAS28  3.2 entered the
maintenance period.
In phase 2, patients who achieved a DAS28  3.2 were
randomized to 1 of 2 step-down maintenance regimens: LEF
monotreatment group (10mg/d) or LEF (10mg/d) plus HCQ
(400mg/d) group. Disease activity was assessed every 12 weeks.
Remission was defined as DAS28  2.6.[11] Relapse of disease
activity was defined as a DAS28 increase ≥ 0.6 from prior
assessment.[12] Patients were followed for up to 48 weeks after
randomization.2.4. Outcome assessment
The primary endpoint was good European League Against
Rheumatism (EULAR) response (i.e., a resulting DAS28
(erythrocyte sedimentation rate [ESR]) < 3.2 and a decrease of
DAS28 by at least 1.2)[13] during the prolonged intensive
treatment. The secondary endpoint was the disease retention
(maintenance of good EULAR response) rate during step-down
maintenance treatment. Clinically relevant predictive factors for
good EULAR response in the prolonged intensive treatment
period and predictive factors for disease flare in the randomized
step-down maintenance period were assessed. Health assessment
questionnaire disability index (HAQ, which had been translated
and validated for the enrolled patients), swollen and tender joint
counts (28 joints), concentration of C-reactive protein, erythro-
cyte sedimentation rate, physician and patient global assessments
(0–10cm visual analog scales), and patient assessed pain and
fatigue (0–10cm visual analog scales) were measured. Rheuma-
toid factor (RF) and anticyclic citrullinated peptide antibodies
were performed by enzyme-linked immunosorbent assay twice at
entry of the intensive and maintenance treatment phases,
respectively. Extra-articular features were acquired, including
rheumatoid nodules, vasculitis, secondary Sjogren syndrome,
interstitial lung disease, and other extra-articular manifestations
associated with RA.2.5. Statistical analysis
A sample size of 344 patients was estimated for the intensive
treatment period with the assumption that 80% of patients
would achieve LDA or remission at the end of intensive treatment
stage (on the basis of the TICORA trial).[14] A sample size of 110
Figure 1. Trial profile. HCQ=hydroxychloroquine, LDA= low disease activity, LEF= leflunomide, MTX=methotrexate.
Table 1
Baseline characteristics of patients enrolled.
Patient characteristics n=346
Female (pt. mo.), n (%) 296 (85.55)
Age (y), mean (SD) 48.69 (12.90)
Initial treatment (pt. mo.), n (%) 122 (35.26)
Disease duration (y), mean (SD) 6.13 (7.33)
Morning stiffness ≥ 1 h, n (%) 198 (57.23)
Extra-articular manifest (pt. mo.), n (%) 110 (31.79)
Pain score (0–10), mean (SD) 6.89 (1.71)
DAS28 score, mean (SD) 6.17 (1.11)
Health assessment questionnaire score, mean (SD) 1.26 (0.67)
Li et al. Medicine (2016) 95:28 www.md-journal.compatients per maintenance treatment group was calculated to have
90%power to detect a 15% difference between the 2 groups with
an a level of 0.05.
In the intensive treatment period, the intention-to-treat
population included all patients who received at least 1 dose
of study drug. Patients who were lost to follow-up, or withdrew
from the trial were designated as nonresponders. In the
randomized maintenance treatment period, the intention-to-treat
population was made up of patients who had randomized and
received at least 1 dose of assigned maintenance treatment. The
safety population included all patients given at least 1 dose of
study drug.
Descriptive statistics, nonparametric test, and x2 test were used
as appropriate. Variables that were significant at P<0.20 on the
univariate analysis were entered into the multivariate model.
Backward multivariate logistic regression analyses were con-
ducted for the baseline predictors of good EULAR response at 12
weeks of the intensive treatment. Cox regression was performed
to analyze the predictors for flare during the maintenance period.
A 2-tailed P value<0.05 was considered significant. Analyses
were performed using the SPSS/PC program (version 16.0;
Chicago, IL).Swollen joint score (0–28), mean (SD) 8.40 (5.75)
Tender joint score (0–28), mean (SD) 12.36 (6.79)
Patient global health (0–10), mean (SD) 6.76 (1.51)
Physician global health (0–10), mean (SD) 6.44 (1.53)
Fatigue score (0–10), mean (SD) 5.66 (1.88)
Erythrocyte sedimentation rate (mm/h), mean (SD) 52.76 (30.27)
C-reactive protein (mg/L), mean (SD) 17.41 (25.31)
Anticycled citrullinated peptide antibody positive, n (%) 281 (81.21)
Rheumatoid factor positive, n (%) 274 (79.19)
DAS28=disease activity score (28 joints), SD = standard deviation.3. Results
3.1. Study population
Three hundred forty-six patients were recruited (Fig. 1), and their
baseline metrics are shown in Table 1. The mean age of patients
was 48.7 years with a mean duration of disease of 6.13 years.
There were 35.3% (122/346) patients who did not received
DMARDs treatment previously. The prevalence of patients who
were receiving 1 or 2 DMARDs treatment at the enrollment was316.8% (58/346). Furthermore, 16.2% (56/346) patients received
oral glucocorticoids (prednisone 10mg/d). ThemeanDAS28 at
baseline was 6.17.
3.2. Response in intensive DMARDs treatment
In phase 1, the proportion of patients achieving a good EULAR
response rose from 18.7% (64/343) to 36.9% (128/344) and
54.1% (187/346) at 12, 24, and 36 weeks. The total proportion
Figure 2. EULAR response for the modified intention-to-treat population of
rheumatoid arthritis patients with intensive disease-modifying antirheumatic
drug treatment. The prevalence of patients achieving good EULAR response
increased 17% to 18% every 12 weeks. EULAR = European League Against
Rheumatism.
Figure 3. Kaplan–Meier curves for disease activity retention over the course of
48-week maintenance treatment. (A) Retention rate in patients with different
disease activity. There were significantly higher disease retention rate in
patients achieving remission (DAS28  2.6) than those achieving LDA (2.6 <
DAS28 3.2) (P=0.046). (B) Retention rate in patients with different functional
activity. There were significantly higher disease retention rate in patients having
low HAQ (0.5) than those having HAQ > 0.5 (P=0.01). (C) Retention rate in
patients with different DAS28 and HAQ. It had been shown that patients
achieving both remission and low HAQ had the highest disease retention rate
during the maintenance period (DAS28  2.6/HAQ  0.5 vs 2.6 < DAS28 
3.2/HAQ > 0.5, P=0.02; vs DAS28  2.6/HAQ > 0.5, P=0.04; vs 2.6 <
DAS28  3.2/HAQ  0.5, P=0.25, respectively). DAS28=disease activity
score (28 joints), HAQ=health assessment questionnaire, LDA= low disease
activity.
Li et al. Medicine (2016) 95:28 Medicineof patients achieving EULAR response (good or moderate) was
75.4% (Fig. 2). The results demonstrate an approximate 18%
increment of good EULAR response rate every 12 weeks,
suggesting that the response continued to improve with
prolonged intensive treatment.
3.3. Maintenance of LDA or remission in maintenance
treatment
In phase 2, 176 patients achieving LDA or remission randomly
entered into the step-down maintenance treatment phase of the
study. By 48 weeks, 36.9% (65/176) patients maintained LDA or
remission. Furthermore, we explored the impact of maintenance
treatment regimens, disease, and functional activity on the
maintenance of LDA.
In the LEF group, 36.8% (32/87) patients remained in LDA. In
the LEF +HCQ group, the proportion of patients remaining LDA
was 37.1% (33/89). For intent-to-treatment population, there
was no difference in disease activity maintenance rate between the
2 groups (data not shown, P=0.53).
Patients achieving remission at initiation of the maintenance
phase had a significantly higher retention rate of disease activity,
compared with those achieving LDA by the point of taper (P=
0.046). Similarly, a higher retention rate of the disease activity
state was showed in patients with a low HAQ (0.5), in
comparison with those with HAQ > 0.5 (P=0.01) at the start of
phase 2. Additionally, patients achieving both remission and low
HAQ had the highest retention rate during the maintenance
period, compared with patients achieving only LDA or high
HAQ (compared with 2.6 < DAS28  3.2/LDA > 0.5, P=0.02;
compared with DAS28  2.6/LDA > 0.5, P=0.04, Fig. 3).
3.4. Predictor analysis
To identify baseline factors that predicted the early response for
the intensive DMARD treatment, we evaluated clinical variables
in patients achieving or failing to achieve a good EULAR
response at 12 weeks. Those with a good EULAR response were
younger (43.8±13.6 years vs 47.9±12.7 years, P=0.03), and
had a lower baseline DAS28 score and ESR (DAS28: 5.98±0.68
vs 6.32±0.92, P=0.001; ESR: 43.08±29.43mm/h vs 56.63±430.14mm/h, P=0.002). Five variables with statistical signifi-
cance at P<0.20 in the bivariate analysis were entered into the
logistic regression analysis: age, number of tender joint, DAS28,
HCQ, and ESR. Age and ESR were independent predictors for
the good EULAR response of the intensive treatment arm (P=
0.03 and P=0.003, Table 2).
Univariate analysis of potential variables associated with a
flare showed that achieving remission (DAS28  2.6) (P=0.07),
pain score (P=0.05), physician global health (P=0.02), fatigue
score (P=0.08), patient global assessment (P=0.09), high HAQ
(>0.5) (P=0.02), and C-reactive protein (P=0.02) at the entry of
maintenance treatment were associated with disease relapse. Cox
regression analysis demonstrated that highHAQ (OR: 2.16, 95%
CI: 1.08–4.32, P=0.03) was an independent risk factor for the
flare (Table 3). LDA or remission maintenance rate was not
associated with the duration of prolonged intensive treatment,
the maintenance treatment regimens, sex, age, and disease
duration (data not shown).
[1]
Table 2
Potential baseline variables associated with achieving good EULAR response during 12 weeks of intensive treatment.
Univariate analysis Multivariate analysis
Variables Good EULAR response (n=64) Moderate or none response (n=208) P OR 95% CI
Female, n (%) 52 (81.25) 176 (84.62) 0.47
Age (y), mean (SD) 43.77 (13.58) 47.92 (12.74) 0.03
∗
0.98 0.96–1.00
Initial treatment, n (%) 22 (34.38) 76 (36.54) 0.75
Disease duration (mo), mean (SD) 70.63 (102.96) 75.60 (84.69) 0.70
TJC (0–28), mean (SD) 11.25 (5.20) 12.27 (6.93) 0.21
SJC (0–28), mean (SD) 7.89 (4.88) 8.33 (5.83) 0.58
Morning stiffness ≥ 1 h, n (%) 42 (65.63) 114 (54.81) 0.13
Extra-articular manifest, n (%) 23 (35.94) 61 (29.33) 0.32
Pain VAS (0–10 cm), mean (SD) 6.84 (1.79) 6.87 (1.68) 0.93
PGA (0–10 cm), mean (SD) 6.73 (1.47) 6.79 (1.52) 0.79
MGA (0–10 cm), mean (SD) 6.53 (1.53) 6.46 (1.57) 0.74
Fatigue VAS (0–10 cm), mean (SD) 5.47 (2.31) 5.75 (1.80) 0.30
DAS28, mean (SD) 5.98 (0.68) 6.32 (0.92) 0.001
∗
HAQ, mean (SD) 1.13 (0.61) 1.28 (0.68) 0.10
ESR (mm/h), mean (SD) 43.08 (29.44) 56.63 (30.14) 0.002
∗
0.98 0.97–0.99
CRP (mg/L), mean (SD) 23.50 (31.96) 28.80 (29.62) 0.23
RF positive, n (%) 47 (75.81) 164 (80.79) 0.39
Anti-CCP antibody positive, n (%) 50 (87.72) 166 (90.71) 0.51
Anti-CCP= anticyclic citrullinated peptide, CI = confidence interval, CRP=C-reactive protein, DAS28=disease activity score (28 joints), ESR= erythrocyte sedimentation rate, EULAR = European League
Against Rheumatism, HAQ=health assessment questionnaire, MGA=medical global assessment, OR = odds ratio, PGA=patient global assessment, RF= rheumatoid factor, SD = standard deviation, SJC=
swollen joint count, TJC= tender joint count, VAS= visual analog scale.
∗
Significant.
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One hundred fifty AEs were reported in 346 patients representing
a prevalence of 43.4% (150/346). The most common AEs were
elevated transaminases (14.16%), and then upper abdominal
illness (13.01%). Twenty-four patients discontinued the study
because of the occurrence of AEs. Eight patients hospitalized for
AEs: 2 upper abdominal illnesses, 2 pneumonia, 1 elevated
transaminase, 1 pulmonary tuberculosis, 1 pneumatothorax, and
1 cerebral hemorrhage (Table 4).
4. Discussion
In 2010, Treat-to-Target (T2T) expert committee recommended
that until the desired treatment target was reached, drugTable 3
Potential variables associated with a flare at the entry of maintenanc
Univariate analy
Variables OR (95% CI)
Female 0.80 (0.43–1.49)
Age, y 1.00 (0.99–1.02)
Disease duration, mo 1.00 (0.99–1.00)
Maintenance regimen (LEF + HCQ) 0.88 (0.56–1.38)
Duration of intensive therapy, mo 1.04 (0.75–1.43)
Pain VAS (0–10 cm) 1.17 (1.00–1.36)
PGA (0–10 cm) 1.20 (0.97–1.47)
MGA (0–10 cm) 1.30 (1.04–1.62)
Fatigue VAS (0–10 cm) 1.13 (0.99–1.30)
Achieving remission (DAS28  2.6) 0.65 (0.40–1.04)
High HAQ (>0.5) 2.22 (1.16–4.23)
ESR, mm/h 1.01 (0.99–1.03)
CRP, mg/L 1.12 (1.02–1.23)
RF positive 1.26 (0.75–2.11)
Anti-CCP antibody positive 1.13 (0.48–2.67)
Anti-CCP= anticyclic citrullinated peptide, CI = confidence interval, CRP=C-reactive protein, DAS28=
questionnaire, HCQ=hydroxychloroquine, LEF= leflunomide, MGA=medical global assessment, OR =
5treatment should be adjusted. New EULAR recommendation
published in 2013 put forward to the idea the treatment target
(remission or at least LDA) should be attained within 6 months
and not necessarily within 3months.[15] However, it is not known
whether remission rate will increase if the intensive DMARDs
therapy is prolonged. In this study, we found high response rate
of RA with prolonged intensive DMARDs therapy. The
proportion of patients with good EULAR response increased
with time without shifting the treatment. There was around 18%
increment of good response rate at 36weeks. The result suggested
that prolonged intensive treatment could be continued and
steered though the treat goal was not reached at 6 months.
Several studies have analyzed the role of baseline character-
istics as predictors of response, such as HAQ, disease duration,e treatment.
sis Multivariate analysis
P OR (95% CI) P
0.48
0.87
0.66
0.57
0.83
0.05
0.09
0.02
0.08
0.07
0.02 2.16 (1.08–4.32) 0.03
0.60
0.02
0.38
0.78
disease activity score (28 joints), ESR= erythrocyte sedimentation rate, HAQ=health assessment
odds ratio, PGA=patient global assessment, RF= rheumatoid factor, VAS= visual analog scale.
[16,17]
Table 4
Safety summary of 346 patients in prolonged intensive treatment.
No. of patients %
Total adverse events 150 43.35
Upper abdominal illness 45 13.01
Elevated transaminase 49 14.16
Leukopenia 34 9.82
Infection
∗
12 3.47
Alopecia 10 2.89
Skin rash 8 2.31
Diarrhea 6 1.73
Thrombocytopenia 6 1.73
Anemia 6 1.73
Proteinuria 6 1.73
Blurred vision 3 0.87
Dizziness 3 0.87
Finger numbness 3 0.87
Itch of skin 2 0.58
Oral ulcer 2 0.58
Cough 2 0.58
Headache 1 0.28
Elevated creatine kinase 1 0.28
Pneumatothorax 1 0.29
Cerebral hemorrhage 1 0.29
Twenty-four adverse events were followed by withdrawal of study drugs: upper abdominal illness 7,
rash 4, elevated transaminase 3, pneumonia 2, herpes zoster 1, leukopenia 1, elevated creatine
kinase 1, dizziness 1, alopecia 1, pneumatothorax 1, cerebral hemorrhage 1, and pulmonary
tuberculosis 1. Eight severe adverse events causing hospitalization were upper abdominal illness 2,
pneumonia 2, elevated transaminase 1, pulmonary tuberculosis 1, pneumatothorax, 1, and cerebral
hemorrhage 1.
∗
Twelve infective events were upper respiratory tract infection 4, pneumonia 3, herpes zoster 2,
urinary infection 1, acute bronchitis 1, and pulmonary tuberculosis 1.
Li et al. Medicine (2016) 95:28 Medicineand baseline disease activity. Sex and age have also been
related to the treatment response.[18–20] In our study, we found
that age and ESRwere the predictors for the outcome of intensive
treatment, which was similar with the previous reports.[20] It
seemed that young patients with low level of ESR were prone to
respond to intensive treatment. Predicting clinical outcomes
based upon baseline factors would be useful to help select the
optimal management of RA.
Our study showed that patients achieving DAS28 remission
and low functional activity (HAQ) had highest retention of their
disease state and by corollary lowest relapse rates. HAQ was an
independent predictor for disease relapse. Thus better control of
disease activity (both clinical and functional) was important for
sustaining the target during intensive treatment. Studies predict-
ing flare of RA are rare. Scirè et al[21] showed that ultrasound
power Doppler (PD)-positive synovial hypertrophy, even in a
single joint, was the main predictor of relapse within 6 months.
Saleem et al[22] reported that baseline PD activity, HAQ, and
DAS28 predicted the flare after remission. Flare was associated
with worse clinical and functional outcomes. Our results further
confirmed the important impact of DAS28 and HAQ on the
maintenance of the treatment target.
In this study, unique conventional DMARDs therapy using
MTX in combination with LEF and HCQ was given to severely
active RA patients. This combination therapy was thought to be
toxic and rarely used in current clinical trials. In our study, good
effect and safety of the triple intensive treatment were found
during 36th week. MTX, as an anchor drug in RA, was the most
common drug in RA treatment. In addition, a number of studies
have shown that LEF has comparable efficacy to MTX.[23–26] In
maintenance period, MTX and prednisone were withdrawn. We6found that there was no advantage on tapering to combination
rather than monotherapy, suggesting that LEF is a good
maintenance treatment as single treatment. Though there were
also some weakness of the study, such as the open label design
and significant dropout, the study evaluated the induction and
maintenance of remission of prolonged intensive DMARDs
treatment at the first time.
In conclusion, the prolonged intensive DMARDs treatment
was an effective treatment strategy for active RA, and a high
remission could be continued and steered though the treat goal
was not reached at 6 months. Higher remission and a lower HAQ
lead to less flare when tapering the DMARDs.Acknowledgment
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